Disc Medicine, Inc. has successfully completed a public offering, raising approximately $422.4 million. This significant capital infusion is intended to support the company's operational and capital expenditure plans, as well as its debt service obligations, extending its financial runway into 2030.

The offering, which closed on October 22, 2026, involved the sale of 6,000,000 shares of common stock at a price of $75.00 per share. Additionally, the company granted underwriters an option to purchase up to 900,000 additional shares, which could bring total proceeds to approximately $485.9 million if fully exercised.

Background

Disc Medicine, Inc. operates within the pharmaceutical preparations industry, as denoted by its SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol IRON. Disc Medicine focuses on developing innovative therapies for hematological diseases, and it has previously undergone name changes, including its rebranding from Gemini Therapeutics, Inc. in February 2021.

What the Filing Says

According to the recent SEC filing (accession number 0001193125-26-429105), the company announced that it had entered into an underwriting agreement with several financial institutions, including Jefferies LLC and Morgan Stanley, to facilitate the offering. The filing stated, "The net proceeds to the Company from the Offering are expected to be approximately $422.4 million."

Impact

This public offering is expected to significantly enhance Disc Medicine's liquidity position, allowing it to fund ongoing projects and potentially accelerate its research and development efforts. The capital raised will also help the company manage its debt obligations effectively, which is crucial for maintaining operational stability.

What's Next

The filing does not specify what happens next, but the company will likely focus on utilizing the proceeds from the offering to support its strategic initiatives and operational goals. Investors and stakeholders will be keenly watching how this capital will be deployed in the coming months.